BI 1026706

BI 1026706 is a potent, orally administered small molecule antagonist of the bradykinin 1 receptor (B1R). It was developed by Boehringer Ingelheim for the treatment of inflammatory conditions, with primary clinical investigation in diabetic macular edema (DME) and chronic obstructive pulmonary disease (COPD). The drug acts by blocking B1R, which is implicated in mediating inflammation and vascular leakage. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and anti-inflammatory effects in patients with DME and COPD. While preclinical studies showed efficacy in reducing retinal vascular permeability via B1R antagonism, clinical results did not demonstrate significant benefit over placebo for DME[3][5]. Trials in COPD focused on its potential to reduce airway inflammation[4][6].

Other names

BI 1026706BI1026706BI-1026706